REV7/REV3L-IN-1
Based on 1 publication(s) in Google Scholar
REV7/REV3L-IN-1 is a REV7/REV3L interaction inhibitor with an IC50 of 78 μM. REV7/REV3L-IN-1 binds directly to REV7 and inhibits its interaction with REV3L. REV7/REV3L-IN-1 inhibits interstrand crosslink repair in cells. REV7/REV3L-IN-1 chemosensitizes cancer cells to Cisplatin (HY-17394). REV7/REV3L-IN-1 can be used in cervical cancer research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.11%
- CAS 番号: 1979192-13-6
- 分子式: C19H21N3O3S
- 分子量:371.45
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 REV7/REV3L-IN-1
MoreDNA/RNA Synthesis アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
IC50: 78 μM (REV7/REV3L interaction)[1]
体外実験
REV7/REV3L-IN-1 (Compound 7) (75 μM; 3 days) inhibits the proliferation of HeLa cells[1].
REV7/REV3L-IN-1 (75 μM; 18 h) inhibits interstrand crosslink repair in COS7 cells transfected with an ICL-containing reporter plasmid[1].
REV7/REV3L-IN-1 (75 μM; 7 days) induces chemosensitization of HeLa cells to Cisplatin treatment and reduces the clonogenic survival rate of cells compared with Cisplatin alone[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HeLa cells
-
Concentration:75 μM
-
Incubation Time:3 days
-
Result:Decreased HeLa cell growth but did not completely eliminate cell viability.
-
Cell Line:HeLa cells
-
Concentration:75 μM
-
Incubation Time:24 h (added 24 h after Cisplatin, followed by 6 days of fresh medium culture)
-
Result:Reduced the normalized number of colonies in HeLa cells treated with cisplatin plus REV7/REV3L-IN-1 compared to cells treated with cisplatin alone, demonstrating a chemosensitization effect.
化学情報
-
CAS 番号 1979192-13-6
-
性状 Solid
-
分子量 371.45
-
分子式 C19H21N3O3S
-
Color Light yellow to yellow
-
SMILES
O=C(C)N1CCC(CN2C=NC(SC=C3C4=CC=C(C)O4)=C3C2=O)CC1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
溶剤 & 溶解度
体外:
DMSO : 100 mg/mL (269.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
プロトコル
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
純度とドキュメンテーション
-
データシート (275 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6922 mL | 13.4608 mL | 26.9215 mL | 67.3038 mL |
| 5 mM | 0.5384 mL | 2.6922 mL | 5.3843 mL | 13.4608 mL | |
| 10 mM | 0.2692 mL | 1.3461 mL | 2.6922 mL | 6.7304 mL | |
| 15 mM | 0.1795 mL | 0.8974 mL | 1.7948 mL | 4.4869 mL | |
| 20 mM | 0.1346 mL | 0.6730 mL | 1.3461 mL | 3.3652 mL | |
| 25 mM | 0.1077 mL | 0.5384 mL | 1.0769 mL | 2.6922 mL | |
| 30 mM | 0.0897 mL | 0.4487 mL | 0.8974 mL | 2.2435 mL | |
| 40 mM | 0.0673 mL | 0.3365 mL | 0.6730 mL | 1.6826 mL | |
| 50 mM | 0.0538 mL | 0.2692 mL | 0.5384 mL | 1.3461 mL | |
| 60 mM | 0.0449 mL | 0.2243 mL | 0.4487 mL | 1.1217 mL | |
| 80 mM | 0.0337 mL | 0.1683 mL | 0.3365 mL | 0.8413 mL | |
| 100 mM | 0.0269 mL | 0.1346 mL | 0.2692 mL | 0.6730 mL |
REV7/REV3L-IN-1 関連分類
HY-100468 関連分類
Powered by Bioz